[go: up one dir, main page]

RU2008136324A - Желудочно-кишечный пролиферативный фактор и его применения - Google Patents

Желудочно-кишечный пролиферативный фактор и его применения Download PDF

Info

Publication number
RU2008136324A
RU2008136324A RU2008136324/13A RU2008136324A RU2008136324A RU 2008136324 A RU2008136324 A RU 2008136324A RU 2008136324/13 A RU2008136324/13 A RU 2008136324/13A RU 2008136324 A RU2008136324 A RU 2008136324A RU 2008136324 A RU2008136324 A RU 2008136324A
Authority
RU
Russia
Prior art keywords
amino acid
acid sequence
use according
seq
mammal
Prior art date
Application number
RU2008136324/13A
Other languages
English (en)
Inventor
Брайан Дж. БОЙЛ (US)
Брайан Дж. БОЙЛ
Уолтер ФАНК (US)
Уолтер Фанк
Макото КАКИТАНИ (JP)
Макото КАКИТАНИ
Такеси ОСИМА (JP)
Такеси ОСИМА
Еун Дзу ПАРК (US)
Еун Дзу ПАРК
Том Й. ТАНГ (US)
Том Й. ТАНГ
Микио ЯГИ (JP)
Микио ЯГИ
Казума ТОМИЗУКА (JP)
Казума ТОМИЗУКА
Original Assignee
АРКА Байофарма,Инк. (US)
АРКА Байофарма,Инк.
Кирин Фарма Кабусики Кайся (Jp)
Кирин Фарма Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АРКА Байофарма,Инк. (US), АРКА Байофарма,Инк., Кирин Фарма Кабусики Кайся (Jp), Кирин Фарма Кабусики Кайся filed Critical АРКА Байофарма,Инк. (US)
Publication of RU2008136324A publication Critical patent/RU2008136324A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)

Abstract

1. Применение полипептида, представляющего собой пролиферативный фактор (GIPF), который содержит (i) аминокислотную последовательность, по меньшей мере на 90% идентичную аминокислотной последовательности SEQ ID NO: 4, или (ii) ее функциональный фрагмент, в качестве активного начала в производстве лекарственного средства для лечения кожных поражений у млекопитающего субъекта путем введения указанному субъекту терапевтически эффективного количества указанного лекарственного средства. ! 2. Применение по п.1, согласно которому полипептид содержит аминокислотную последовательность, которая по меньшей мере на 90% идентична аминокислотной последовательности SEQ ID NO: 10. ! 3. Применение по п.2, согласно которому полипептид состоит из аминокислотной последовательности SEQ ID NO: 10. ! 4. Применение по любому из пп.1-3, согласно которому под кожным поражением подразумевается рана. ! 5. Применение по п.4, согласно которому рана представляет собой ожог. ! 6. Применение по любому из пп.1-3 или 5, согласно которому млекопитающим субъектом является человек. ! 7. Применение по п.4, согласно которому млекопитающим субъектом является человек.

Claims (7)

1. Применение полипептида, представляющего собой пролиферативный фактор (GIPF), который содержит (i) аминокислотную последовательность, по меньшей мере на 90% идентичную аминокислотной последовательности SEQ ID NO: 4, или (ii) ее функциональный фрагмент, в качестве активного начала в производстве лекарственного средства для лечения кожных поражений у млекопитающего субъекта путем введения указанному субъекту терапевтически эффективного количества указанного лекарственного средства.
2. Применение по п.1, согласно которому полипептид содержит аминокислотную последовательность, которая по меньшей мере на 90% идентична аминокислотной последовательности SEQ ID NO: 10.
3. Применение по п.2, согласно которому полипептид состоит из аминокислотной последовательности SEQ ID NO: 10.
4. Применение по любому из пп.1-3, согласно которому под кожным поражением подразумевается рана.
5. Применение по п.4, согласно которому рана представляет собой ожог.
6. Применение по любому из пп.1-3 или 5, согласно которому млекопитающим субъектом является человек.
7. Применение по п.4, согласно которому млекопитающим субъектом является человек.
RU2008136324/13A 2004-01-27 2008-09-09 Желудочно-кишечный пролиферативный фактор и его применения RU2008136324A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53960504P 2004-01-27 2004-01-27
US60/539.605 2004-01-27
US61924104P 2004-10-15 2004-10-15
US60/619.241 2004-10-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2006130791/13A Division RU2343158C2 (ru) 2004-01-27 2005-01-27 Желудочно-кишечный пролиферативный фактор и его применения

Publications (1)

Publication Number Publication Date
RU2008136324A true RU2008136324A (ru) 2010-03-20

Family

ID=34830487

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2006130791/13A RU2343158C2 (ru) 2004-01-27 2005-01-27 Желудочно-кишечный пролиферативный фактор и его применения
RU2008136324/13A RU2008136324A (ru) 2004-01-27 2008-09-09 Желудочно-кишечный пролиферативный фактор и его применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2006130791/13A RU2343158C2 (ru) 2004-01-27 2005-01-27 Желудочно-кишечный пролиферативный фактор и его применения

Country Status (14)

Country Link
US (4) US20050256036A1 (ru)
EP (1) EP1727560B1 (ru)
JP (1) JP2007526248A (ru)
KR (1) KR20070007289A (ru)
AU (1) AU2005208945A1 (ru)
BR (1) BRPI0507168A (ru)
CA (1) CA2554403A1 (ru)
IL (1) IL177060A0 (ru)
MX (1) MXPA06008495A (ru)
NO (1) NO20063522L (ru)
RU (2) RU2343158C2 (ru)
SG (1) SG149059A1 (ru)
TW (1) TW200536859A (ru)
WO (1) WO2005072419A2 (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2157192T3 (pl) 2003-10-10 2014-01-31 Deutsches Krebsforsch Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)
US20190330295A1 (en) * 2005-05-04 2019-10-31 Zealand Pharma A/S Glucagon-like-peptide-2 (glp-2) analogues
EP1942926A4 (en) * 2005-10-07 2010-06-16 Nuvelo Inc STEM CELL FACTOR ARTIFICIAL PROTEIN SCFA1 AND ITS USES
JP2010509919A (ja) 2006-11-15 2010-04-02 マサチューセッツ・アイ・アンド・イア・インファーマリー 内耳細胞の生成
WO2008088524A2 (en) * 2006-12-28 2008-07-24 Nuvelo, Inc. Thrombospondin-domain-deficient r-spondin 1 protein as gastrointestinal tract epithelial proliferation factor
EP3424529A1 (en) 2007-07-02 2019-01-09 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US9464275B2 (en) * 2008-08-21 2016-10-11 The Board Of Trustees Of The Leland Stanford Junior University Ex vivo culture, proliferation and expansion of intestinal epithelium
AU2009316264B2 (en) * 2008-11-24 2016-09-15 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
EP2393917B1 (en) 2009-02-03 2016-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells.
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
IT1396935B1 (it) 2009-11-26 2012-12-20 Solartium Entpr Ltd Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici
RU2532323C2 (ru) * 2011-06-20 2014-11-10 Мапикс Эс.Эй.Ар.Эл. Лекарственное средство для лечения патологического синдрома и способ лечения функциональных нарушений кишечника
GB201106395D0 (en) * 2011-04-14 2011-06-01 Hubrecht Inst Compounds
CN106167526A (zh) 2011-07-15 2016-11-30 昂考梅德药品有限公司 Rspo结合剂和其应用
AU2013289990B2 (en) 2012-07-13 2018-06-14 Oncomed Pharmaceuticals, Inc. RSPO3 binding agents and uses thereof
JP2015527398A (ja) 2012-09-07 2015-09-17 マサチューセッツ アイ アンド イヤー インファーマリー 聴覚喪失治療
KR102133789B1 (ko) * 2013-01-10 2020-07-14 바이오콘 리미티드 유가식 모델을 이용한 피키아 파스토리스에서 재조합 단백질의 발현 방법
US20170314027A1 (en) 2014-08-06 2017-11-02 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
TW201628648A (zh) 2014-09-16 2016-08-16 安可美德藥物股份有限公司 纖維變性疾病之治療
CA3009153A1 (en) 2015-01-30 2016-08-04 The University Of North Carolina At Chapel Hill Methods to generate gastrointestinal epithelial tissue constructs
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
KR20180117628A (ko) 2016-01-29 2018-10-29 매사추세츠 아이 앤드 이어 인퍼머리 내이 지지 세포의 확장 및 분화 및 그의 사용 방법
US11180735B2 (en) 2016-10-28 2021-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods to preserve tumor-stromal interactions in culture and therapeutic predictive applications thereof
WO2018229252A1 (en) 2017-06-16 2018-12-20 Zealand Pharma A/S Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
CA3093581A1 (en) 2018-05-15 2019-11-21 The University Of North Carolina At Chapel Hill Devices, systems and apparatuses for generating self-sustaining hypoxic conditions and gaseous and non-gaseous chemical gradients for in vitro cell culture
US20230098968A1 (en) 2018-05-25 2023-03-30 The University Of North Carolina At Chapel Hill Formation of arrays of planar intestinal crypts possessing a stem/proliferative cell compartment and differentiated cell zone
JP2022511375A (ja) 2018-11-16 2022-01-31 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル インビトロ細胞培養粘液系
WO2021247497A1 (en) * 2020-06-03 2021-12-09 Children's Hospital Medical Center Compositions and methods comprising r-spondins for treatment of tumors
AU2022278682A1 (en) 2021-05-21 2024-01-18 Emblation Limited Microwave treatment of tissue
US12465781B2 (en) 2021-06-11 2025-11-11 Joon Bu Park Negative Poisson's ratio materials for thermal and radiation therapy seeds
WO2023097236A1 (en) * 2021-11-24 2023-06-01 The Rockefeller University Compositions and methods for generating immunoglobulin knock-in mice

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115608A0 (en) * 1994-10-13 1996-01-19 Amgen Inc Stabilized analogs of keratinocyte growth factor
US6824973B2 (en) * 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
EP1268543A2 (en) * 2000-04-05 2003-01-02 Kirin Beer Kabushiki Kaisha Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US7411052B2 (en) * 2001-03-05 2008-08-12 Nuvelo, Inc. Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
US20030032034A1 (en) * 2001-03-05 2003-02-13 Tang Y. Tom Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
ATE553193T1 (de) * 2001-08-30 2012-04-15 Arca Biopharma Inc Verfahren und materialien in verbindung mit stammzellen-wachstumsfaktor-ähnlichen polypeptiden und polynukleotiden
EP1434796A2 (en) 2001-10-03 2004-07-07 Incyte Genomics, Inc. Secreted proteins
EP1504099A4 (en) * 2001-12-10 2006-05-10 Nuvelo Inc NEW NUCLEIC ACIDS AND POLYPEPTIDES
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US20050054829A1 (en) * 2003-07-22 2005-03-10 Wiley Steven R. Compositions and methods relating to TSP-30a, b, c and d
US20050169995A1 (en) * 2003-10-03 2005-08-04 Kuo Calvin J. Modulation of gastrointestinal epithelium proliferation through the Wnt signaling pathway
PL2157192T3 (pl) * 2003-10-10 2014-01-31 Deutsches Krebsforsch Kompozycje do diagnozowania i terapii chorób związanych z nieprawidłową ekspresją futrin (R-spondin)

Also Published As

Publication number Publication date
IL177060A0 (en) 2008-03-20
US20050256036A1 (en) 2005-11-17
KR20070007289A (ko) 2007-01-15
AU2005208945A1 (en) 2005-08-11
RU2343158C2 (ru) 2009-01-10
JP2007526248A (ja) 2007-09-13
TW200536859A (en) 2005-11-16
EP1727560B1 (en) 2012-09-12
WO2005072419A2 (en) 2005-08-11
US7951381B2 (en) 2011-05-31
SG149059A1 (en) 2009-01-29
WO2005072419A3 (en) 2007-06-28
US20080300183A1 (en) 2008-12-04
RU2006130791A (ru) 2008-03-27
BRPI0507168A (pt) 2007-06-26
US20100137210A1 (en) 2010-06-03
US20050256044A1 (en) 2005-11-17
NO20063522L (no) 2006-10-25
CA2554403A1 (en) 2005-08-11
EP1727560A4 (en) 2009-09-09
MXPA06008495A (es) 2007-05-23
EP1727560A2 (en) 2006-12-06

Similar Documents

Publication Publication Date Title
RU2008136324A (ru) Желудочно-кишечный пролиферативный фактор и его применения
CA2596597A1 (en) Method for stimulation collagen synthesis and/or kgf expression
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
NZ608502A (en) Polypeptides that bind to human complement component c5
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
JP2005537234A5 (ru)
RU2010144014A (ru) Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств
NZ578928A (en) Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases
MX2009012742A (es) Ingrediente activo novedoso en cicatrizacion y uso del mismo.
CN103097405B (zh) 用于伤口愈合的新型肽
MX2008009493A (es) Peptido novedoso y uso del mismo.
RU2011108486A (ru) ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА
EA200900095A1 (ru) Лекарственные формы бифосфонатов для ингаляции и способы их применения
JP2008526935A5 (ru)
DE60227670D1 (de) Aminosäuren-enthaltende zusammensetzungen, geeignet zur wundheilung, insbesondere zur behandlung des auges
RU2011110711A (ru) Новые биологически активные пептиды и их новое применение
NO20081453L (no) Sammensetninger og fremgangsmater for diagnostisering og behandling av inflammasjon
MX2011007108A (es) Incrementadores de angiogenesis generados por derrame cerebral y usos de los mismos.
WO2008096816A1 (ja) 血管新生誘導剤及びそれに用いられるポリペプチド
MX2022008748A (es) Administración oral de péptidos.

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20111012